SEARCH

SEARCH BY CITATION

References

  • 1
    Sorm F,Piskala A,Cihak A,Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964; 20: 2023.
  • 2
    Jones PA,Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20: 8593.
  • 3
    Silverman LR,Demakos EP,Peterson BL,Kornblith AB,Holland JC,Odchimar-Reissig R,Stone RM,Nelson D,Powell BL,DeCastro CM,Ellerton J,Larson RA, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 242940.
  • 4
    Kantarjian H,Issa JP,Rosenfeld CS,Bennett JM,Albitar M,DiPersio J,Klimek V,Slack J,de Castro C,Ravandi F,Helmer R,III,Shen L, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794803.
  • 5
    Lyko F,Brown R. DNA methyltransferase inhibitors and the establishment of epigenetic cancer therapies. J Natl Cancer Inst 2005; 97: 1498506.
  • 6
    Yoo CB,Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 2006; 5: 3750.
  • 7
    Chuang JC,Yoo CB,Kwan JM,Li TW,Liang G,Yang AS,Jones PA. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 2005; 4: 151520.
  • 8
    Stresemann C,Brueckner B,Musch T,Stopper H,Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 2006; 66: 2794800.
  • 9
    Egger G,Liang G,Aparicio A,Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 45763.
  • 10
    Mund C,Hackanson B,Stresemann C,Lubbert M,Lyko F. Characterization of DNA demethylation effects induced by 5-Aza-2′-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res 2005; 65: 708690.
  • 11
    Yang AS,Doshi KD,Choi SW,Mason JB,Mannari RK,Gharybian V,Luna R,Rashid A,Shen L,Estecio MR,Kantarjian HM,Garcia-Manero G, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006; 66: 5495503.
  • 12
    Gore SD,Baylin S,Sugar E,Carraway H,Miller CB,Carducci M,Grever M,Galm O,Dauses T,Karp JE,Rudek MA,Zhao M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66: 63619.
  • 13
    Soriano AO,Yang H,Faderl S,Estrov Z,Giles F,Ravandi F,Cortes J,Wierda WG,Ouzounian S,Quezada A,Pierce S,Estey EH, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110: 23028.
  • 14
    Mund C,Brueckner B,Lyko F. Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 2006; 1: 713.
  • 15
    Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8: 28698.
  • 16
    Daskalakis M,Nguyen TT,Nguyen C,Guldberg P,Kohler G,Wijermans P,Jones PA,Lübbert M. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100: 295764.
  • 17
    Notari RE,DeYoung JL. Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions. J Pharm Sci 1975; 64: 114857.
  • 18
    Lin KT,Momparler RL,Rivard GE High-performance liquid chromatographic analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 1981; 70: 122832.
  • 19
    Tomankova H,Zyka J. Study of the time dependence of the stability of 5-aza-2′-deoxycytidine in acid medium. Microchem J 1980; 25: 2818.
  • 20
    Stach D,Schmitz OJ,Stilgenbauer S,Benner A,Dohner H,Wiessler M,Lyko F. Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003; 31: e2.
  • 21
    Yoo CB,Jeong S,Egger G,Liang G,Phiasivongsa P,Tang C,Redkar S,Jones PA. Delivery of 5-aza-2′-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 2007; 67: 64008.
  • 22
    Marcucci G,Silverman L,Eller M,Lintz L,Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005; 45: 597602.
  • 23
    Chabot GG,Rivard GE,Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2′-deoxycytidine in rabbits and dogs. Cancer Res 1983; 43: 5927.
  • 24
    Chabot GG,Bouchard J,Momparler RL. Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 1983; 32: 13278.
  • 25
    Zhao M,Rudek MA,He P,Hartke C,Gore S,Carducci MA,Baker SD. Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 813: 818.
  • 26
    Liu Z,Marcucci G,Byrd JC,Grever M,Xiao J,Chan KK. Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 2006; 20: 111726.
  • 27
    Bender CM,Gonzalgo ML,Gonzales FA,Nguyen CT,Robertson KD,Jones PA. Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol 1999; 19: 66908.
  • 28
    Samlowski WE,Leachman SA,Wade M,Cassidy P,Porter-Gill P,Busby L,Wheeler R,Boucher K,Fitzpatrick F,Jones DA,Karpf AR. Evaluation of a 7-Day Continuous Intravenous Infusion of Decitabine: inhibition of Promoter-Specific and Global Genomic DNA Methylation. J Clin Oncol 2005; 23: 3897905.
  • 29
    Lavelle D,Chin J,Vaitkus K,Redkar S,Phiasivongsa P,Tang C,Will R,Hankewych M,Roxas B,Singh M,Saunthararajah Y,Desimone J. Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis. Am J Hematol 2007; 82: 9815.
  • 30
    Gaudet F,Hodgson JG,Eden A,Jackson-Grusby L,Dausman J,Gray JW,Leonhardt H,Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300: 48992.
  • 31
    Howard G,Eiges R,Gaudet F,Jaenisch R,Eden A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 2008; 27: 4048.
  • 32
    Kantarjian H,Oki Y,Garcia-Manero G,Huang X,O'Brien S,Cortes J,Faderl S,Bueso-Ramos C,Ravandi F,Estrov Z,Ferrajoli A,Wierda WG, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 527.
  • 33
    Vesely J,Seifert J,Cihak A,Sorm F. Biochemical changes associated with the development of resistance to 5-azacytidine in AKR leukemic mice. Int J Cancer 1966; 1: 319.
  • 34
    Pastor-Anglada M,Cano-Soldado P,Molina-Arcas M,Lostao MP,Larrayoz I,Martinez-Picado J,Casado FJ. Cell entry and export of nucleoside analogues. Virus Res 2005; 107: 15164.
  • 35
    Hubeek I,Stam RW,Peters GJ,Broekhuizen R,Meijerink JP,van Wering ER,Gibson BE,Creutzig U,Zwaan CM,Cloos J,Kuik DJ,Pieters R, et al. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005; 93: 138894.
  • 36
    Marce S,Molina-Arcas M,Villamor N,Casado FJ,Campo E,Pastor-Anglada M,Colomer D. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 2006; 91: 895902.
  • 37
    Molina-Arcas M,Bellosillo B,Casado FJ,Montserrat E,Gil J,Colomer D,Pastor-Anglada M. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 2003; 101: 232834.
  • 38
    Pastor-Anglada M,Molina-Arcas M,Casado FJ,Bellosillo B,Colomer D,Gil J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia 2004; 18: 38593.
  • 39
    Mackey JR,Mani RS,Selner M,Mowles D,Young JD,Belt JA,Crawford CR,Cass CE. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 434957.
  • 40
    Garcia-Manteiga J,Molina-Arcas M,Casado FJ,Mazo A,Pastor-Anglada M. Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine- induced cytotoxicity. Clin Cancer Res 2003; 9: 50008.
  • 41
    Huang Y,Anderle P,Bussey KJ,Barbacioru C,Shankavaram U,Dai Z,Reinhold WC,Papp A,Weinstein JN,Sadee W. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004; 64: 4294301.
  • 42
    Spratlin J,Sangha R,Glubrecht D,Dabbagh L,Young JD,Dumontet C,Cass C,Lai R,Mackey JR. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 695661.
  • 43
    Momparler RL,Derse D. Kinetics of phosphorylation of 5-aza-2′-deoxyycytidine by deoxycytidine kinase. Biochem Pharmacol 1979; 28: 14434.
  • 44
    Van Rompay AR,Norda A,Linden K,Johansson M,Karlsson A. Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases. Mol Pharmacol 2001; 59: 11816.
  • 45
    Stegmann AP,Honders MW,Willemze R,Landegent JE. De novo induced mutations in the deoxycytidine kinase (dck) gene in rat leukemic clonal cell lines confer resistance to cytarabine (AraC) and 5-aza-2′-deoxycytidine (DAC). Leukemia 1995; 9: 10328.
  • 46
    Eliopoulos N,Cournoyer D,Momparler RL. Drug resistance to 5-aza-2′-deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 1998; 42: 3738.
  • 47
    Li LH,Olin EJ,Buskirk HH,Reineke LM. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 1970; 30: 27609.
  • 48
    Choi SH,Byun HM,Kwan JM,Issa JP,Yang AS. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 2007; 138: 61623.
  • 49
    Santi DV,Norment A,Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984; 81: 69937.
  • 50
    Chen L,MacMillan AM,Chang W,Ezaz-Nikpay K,Lane WS,Verdine GL. Direct identification of the active-site nucleophile in a DNA (cytosine-5)-methyltransferase. Biochemistry 1991; 30: 1101825.
  • 51
    Schermelleh L,Spada F,Easwaran HP,Zolghadr K,Margot JB,Cardoso MC,Leonhardt H. Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat Methods 2005; 2: 7516.
  • 52
    Ghoshal K,Datta J,Majumder S,Bai S,Kutay H,Motiwala T,Jacob ST. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005; 25: 472741.
  • 53
    Palii SS,Van Emburgh BO,Sankpal UT,Brown KD,Robertson KD. The DNA methylation inhibitor 5-aza-2′-deoxycytidine (5-azadC) induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases (DNMTs) 1 and 3B. Mol Cell Biol 2008; 28: 75271.
  • 54
    Mortusewicz O,Schermelleh L,Walter J,Cardoso MC,Leonhardt H. Recruitment of DNA methyltransferase I to DNA repair sites. Proc Natl Acad Sci USA 2005; 102: 89059.
  • 55
    Flatau E,Gonzales FA,Michalowsky LA,Jones PA. DNA methylation in 5-aza-2′-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells. Mol Cell Biol 1984; 4: 2098102.
  • 56
    Weisenberger DJ,Velicescu M,Cheng JC,Gonzales FA,Liang G,Jones PA. Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2004; 2: 6272.
  • 57
    Liu Z,Liu S,Xie Z,Blum W,Perrotti D,Paschka P,Klisovic R,Byrd J,Chan KK,Marcucci G. Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Res 2007; 35: e31.